Metastatic Pancreatic Cancer Clinical Trial
Official title:
Tablet-based Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced NSCLC or Advanced Pancreatic Cancer With Focus on Cancer Cachexia
Evaluation of patient reported outcomes (PRO) with tumor cachexia in a real life setting.
The PRO Xie project will recruit a representative cohort of patients with advanced lung or
advanced pancreatic cancer with a high risk for the development of cancer cachexia.
Patient Reported Outcomes (PRO) are assessed in a real life setting by a questionnaire
consisting of 20 questions: QoL is measured by SF12, fatigue by FACIT-F and cachexia by FAACT
questionnaires, respectively.
These data will determine the potential need for anti-cachexia treatment in those patients,
as well as the number of underweight patients, the evaluation of general QoL, fatigue and
cachexia and the evaluation of malnutrition.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04753879 -
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
|
Phase 2 | |
Completed |
NCT01417000 -
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02975141 -
Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer
|
Phase 1 | |
Active, not recruiting |
NCT00761345 -
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT00919282 -
Gemcitabine (GFF) in Patients With Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT01088815 -
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
Completed |
NCT04133155 -
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
|
||
Withdrawn |
NCT05251038 -
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04612530 -
PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03602885 -
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
|
N/A | |
Recruiting |
NCT05442749 -
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03721744 -
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT03261947 -
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
|
Phase 2 | |
Withdrawn |
NCT06017323 -
Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 1 | |
Terminated |
NCT01946646 -
Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT01523457 -
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
Terminated |
NCT00726037 -
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00744640 -
Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
|
Phase 1/Phase 2 |